Ashesha Mechineni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashesha Mechineni has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Rajapriya Manickam
Pulmonary and Critical Care Medicine, St. Joseph's Regional Medical Center, Paterson, USA
6 shared publications - Balraj Singh
Saint Joseph's University Medical Center, Paterson, NJ, United States
3 shared publications - Anish Samuel
St. Joseph's University Medical Center, United States
2 shared publications Balraj Singh
St Joseph's University Medical Center Paterson NJ USA
2 shared publications- Parminder Kaur
Cardiology, Saint Joseph's University Medical Center, Paterson, USA
2 shared publications Rajapriya Manickam
St Joseph's University Medical Center Paterson NJ USA
2 shared publications
Latest Publications
- Open Access
- 1 May 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (9) , P3-P4
Philips Respironics Recalled CPAP/BPAP Masks
- 1 May 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (9) , P3-P4
Open AccessPhilips Respironics Recalled CPAP/BPAP Masks
- Open Access
- 8 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22061
Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis
Studies suggest that COVID-19 infection may induce increased hypercoagulability, leading to thrombotic complications. The high rates of thrombotic complications among patients receiving standard-dose deep venous thrombosis (DVT) prophylaxis have prompted some clinicians to support the empiric increase of anticoagulation (AC) doses used for prophylaxis in patients with COVID-19. At present, the optimal anticoagulant agents, dosages, and duration have not been designated. We conducted a retrospective study to assess for outcomes in patients who received treatment for COVID-19 based on various dosings of AC. This was a single-institution, retrospective cross-sectional study including patients with a positive COVID-19 test who were admitted within the St. Joseph’s Health Network from September to November of 2020. The inclusion criteria were men and women aged 18 years or older who had confirmed COVID-19 by polymerase chain reaction (PCR). Medical charts of patients who met the inclusion criteria were audited to obtain information. The patients were separated into three cohorts: those who received DVT prophylactic dose of AC, those who received an intermediate dose of AC, and those who received therapeutic AC. A total of 440 patients were included in the study, of whom 236 were Hispanic (50.3%), 131 were Caucasian (27.1%), 47 were African American (10.7%), and 26 were Asian (5.9%). The most common comorbidities were hypertension (273/440 [62.2%]), diabetes 189/440 [43.1%]), and coronary artery disease (60/440 [13.7%]). In the DVT prophylactic dose of AC cohort, there were 215 patients, and the average length of stay was 10.3 days. Eleven patients experienced bleeding events, five patients experienced thrombotic events, 16 patients required mechanical ventilation, and 20 patients died. In the intermediate dose of AC cohort, there were 63 patients, and the average length of stay was 10.3 days. Three patients experienced bleeding events, two patients experienced thrombotic events, seven patients required mechanical invasive ventilation, and 11 patients died. In the therapeutic dose of AC cohort, there were 162 patients, and the average length of stay was 14 days. In this cohort, 19 patients experienced bleeding events, 12 patients experienced thrombotic events, 26 patients required invasive mechanical ventilation, and 29 patients died. Patients who received intermediate dosing of AC also had the lowest risk of thrombotic events (0.05). Patients who received intermediate dosing of AC had the lowest rates of requiring both high-flow nasal cannula (p = 0.0001) and invasive mechanical ventilation (p = 0.031). Patients who received intermediate dosing of AC had a lower rate of bleeding compared to those who received the DVT prophylaxis dose and systemic AC dose (p = 0.037). The DVT prophylactic and intermediate dosing of AC groups had a shorter length of stay in comparison to the systemic AC group (p = 0.0002). In comparison to the venous thromboembolism prophylaxis dose and systemic AC dose groups, intermediate dosing of AC had the lowest rates of hemorrhage, mortality, length of stay, and requirement of high-flow nasal cannula or mechanical invasive ventilation. In the systemic dose AC group, there were worse clinical outcomes in terms of length of stay, incidence of bleeding events, requirement of mechanical ventilator use, and rate of mortality.
- 8 February 2022
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e22061
Open AccessUse of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis
Studies suggest that COVID-19 infection may induce increased hypercoagulability, leading to thrombotic complications. The high rates of thrombotic complications among patients receiving standard-dose deep venous thrombosis (DVT) prophylaxis have prompted some clinicians to support the empiric increase of anticoagulation (AC) doses used for prophylaxis in patients with COVID-19. At present, the optimal anticoagulant agents, dosages, and duration have not been designated. We conducted a retrospective study to assess for outcomes in patients who received treatment for COVID-19 based on various dosings of AC. This was a single-institution, retrospective cross-sectional study including patients with a positive COVID-19 test who were admitted within the St. Joseph’s Health Network from September to November of 2020. The inclusion criteria were men and women aged 18 years or older who had confirmed COVID-19 by polymerase chain reaction (PCR). Medical charts of patients who met the inclusion criteria were audited to obtain information. The patients were separated into three cohorts: those who received DVT prophylactic dose of AC, those who received an intermediate dose of AC, and those who received therapeutic AC. A total of 440 patients were included in the study, of whom 236 were Hispanic (50.3%), 131 were Caucasian (27.1%), 47 were African American (10.7%), and 26 were Asian (5.9%). The most common comorbidities were hypertension (273/440 [62.2%]), diabetes 189/440 [43.1%]), and coronary artery disease (60/440 [13.7%]). In the DVT prophylactic dose of AC cohort, there were 215 patients, and the average length of stay was 10.3 days. Eleven patients experienced bleeding events, five patients experienced thrombotic events, 16 patients required mechanical ventilation, and 20 patients died. In the intermediate dose of AC cohort, there were 63 patients, and the average length of stay was 10.3 days. Three patients experienced bleeding events, two patients experienced thrombotic events, seven patients required mechanical invasive ventilation, and 11 patients died. In the therapeutic dose of AC cohort, there were 162 patients, and the average length of stay was 14 days. In this cohort, 19 patients experienced bleeding events, 12 patients experienced thrombotic events, 26 patients required invasive mechanical ventilation, and 29 patients died. Patients who received intermediate dosing of AC also had the lowest risk of thrombotic events (0.05). Patients who received intermediate dosing of AC had the lowest rates of requiring both high-flow nasal cannula (p = 0.0001) and invasive mechanical ventilation (p = 0.031). Patients who received intermediate dosing of AC had a lower rate of bleeding compared to those who received the DVT prophylaxis dose and systemic AC dose (p = 0.037). The DVT prophylactic and intermediate dosing of AC groups had a shorter length of stay in comparison to the systemic AC group (p = 0.0002). In comparison to the venous thromboembolism prophylaxis dose and systemic AC dose groups, intermediate dosing of AC had the lowest rates of hemorrhage, mortality, length of stay, and requirement of high-flow nasal cannula or mechanical invasive ventilation. In the systemic dose AC group, there were worse clinical outcomes in terms of length of stay, incidence of bleeding events, requirement of mechanical ventilator use, and rate of mortality.
- Open Access
- 10 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21081
Pulmonary Sclerosing Pneumocytoma: An Essential Differential Diagnosis for a Lung Nodule
Pulmonary sclerosing pneumocytoma, previously known as pulmonary sclerosing hemangioma, is a rare benign lung tumor with a low prevalence. We present this condition in a 26-year-old, young, non-smoking female with a slow-growing pulmonary nodule incidentally noted on imaging. Serial computed tomography(CT) scans revealed slow growth, and invasive testing was recommended. The patient underwent a left lateral thoracotomy and based on frozen section findings. A left lower lobectomy was performed. The final pathological diagnosis revealed sclerosing pneumocytoma. This is an atypical patient demographic considering the propensity of the disease for middle-aged Asian women. The case presentation and work-up highlight this critical differential diagnosis for incidental pulmonary nodules increasingly being noted due to widespread use of imaging for screening and routine care in the current medical climate. There are no specific imaging criteria to diagnose this condition. The final diagnosis is made only after surgical biopsy and histopathology. No additional treatment is needed following the diagnosis.
- 10 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e21081
Open AccessPulmonary Sclerosing Pneumocytoma: An Essential Differential Diagnosis for a Lung Nodule
Pulmonary sclerosing pneumocytoma, previously known as pulmonary sclerosing hemangioma, is a rare benign lung tumor with a low prevalence. We present this condition in a 26-year-old, young, non-smoking female with a slow-growing pulmonary nodule incidentally noted on imaging. Serial computed tomography(CT) scans revealed slow growth, and invasive testing was recommended. The patient underwent a left lateral thoracotomy and based on frozen section findings. A left lower lobectomy was performed. The final pathological diagnosis revealed sclerosing pneumocytoma. This is an atypical patient demographic considering the propensity of the disease for middle-aged Asian women. The case presentation and work-up highlight this critical differential diagnosis for incidental pulmonary nodules increasingly being noted due to widespread use of imaging for screening and routine care in the current medical climate. There are no specific imaging criteria to diagnose this condition. The final diagnosis is made only after surgical biopsy and histopathology. No additional treatment is needed following the diagnosis.
- 16 August 2021
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 20 (11) , 1299-1307
Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness
Remdesivir is a nucleoside analog, which inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained promin...
- 16 August 2021
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 20 (11) , 1299-1307
Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness
Remdesivir is a nucleoside analog, which inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained promin...
- Open Access
- 27 July 2021
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 34, 101483
The importance in early identification of a herpetic endobronchial mass
- 27 July 2021
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 34, 101483
Open AccessThe importance in early identification of a herpetic endobronchial mass
- Open Access
- 23 June 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (6) , e04341
Emphysematous cholecystitis: A deadly disguise of a common culprit
Emphysematous cholecystitis is a critical differential diagnosis for physicians to consider when evaluating patients with acute abdomen. Patients who are unable to undergo emergency surgery can benefit from percutaneous cholecystostomy.
- 23 June 2021
- Published by Wiley in Clinical Case Reports
- Vol. 9 (6) , e04341
Open AccessEmphysematous cholecystitis: A deadly disguise of a common culprit
Emphysematous cholecystitis is a critical differential diagnosis for physicians to consider when evaluating patients with acute abdomen. Patients who are unable to undergo emergency surgery can benefit from percutaneous cholecystostomy.
- Open Access
- 1 April 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 43 (2) , 214-218
COVID-19 and bleeding at unusual locations: Report of four cases
- 1 April 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 43 (2) , 214-218
Open AccessCOVID-19 and bleeding at unusual locations: Report of four cases
- Open Access
- 15 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
A Rare Presentation of a Rare Case: Acute Respiratory Failure in Swyer-James-Macleod Syndrome
Swyer-James-Macleod syndrome (SJMS) is a rare clinical entity acquired during childhood due to a respiratory infection leading to bronchiolitis obliterans. This inciting event is hypothesized to cause structural and functional changes of the developing alveoli, terminal bronchioles, and the corresponding pulmonary vasculature, resulting in emphysematous changes and a matched ventilation-perfusion defect. We present a 67-year-old male patient with hypercapnic respiratory failure requiring invasive mechanical ventilation, who had typical features of SJMS undiagnosed before this admission. He was extubated successfully, discharged home, and continues to be stable at a 90-day follow-up period. This marks one of the rare accounts where a patient with SJMS was given ventilatory support emergently, and one of the oldest patients reported. SJMS is under-reported due to its indolent clinical course and misdiagnosed as some other pulmonary abnormality. The clinical course progression and prognosis are unclear and variable in many affected patients due to this condition's rarity.
- 15 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
Open AccessA Rare Presentation of a Rare Case: Acute Respiratory Failure in Swyer-James-Macleod Syndrome
Swyer-James-Macleod syndrome (SJMS) is a rare clinical entity acquired during childhood due to a respiratory infection leading to bronchiolitis obliterans. This inciting event is hypothesized to cause structural and functional changes of the developing alveoli, terminal bronchioles, and the corresponding pulmonary vasculature, resulting in emphysematous changes and a matched ventilation-perfusion defect. We present a 67-year-old male patient with hypercapnic respiratory failure requiring invasive mechanical ventilation, who had typical features of SJMS undiagnosed before this admission. He was extubated successfully, discharged home, and continues to be stable at a 90-day follow-up period. This marks one of the rare accounts where a patient with SJMS was given ventilatory support emergently, and one of the oldest patients reported. SJMS is under-reported due to its indolent clinical course and misdiagnosed as some other pulmonary abnormality. The clinical course progression and prognosis are unclear and variable in many affected patients due to this condition's rarity.
- Open Access
- 30 January 2021
- Published by Wiley
Emphysematous cholecystitis: A deadly disguise of a common culprit.
Emphysematous cholecystitis is caused by gas-forming micro-organisms, primarily in patients with immunosuppression and diabetes mellitus. It leads to a signature radiological finding with air in gall bladder wall as described in this report. Clinicians should be aware of this critical differential diagnosis.
- 30 January 2021
- Published by Wiley
Open AccessEmphysematous cholecystitis: A deadly disguise of a common culprit.
Emphysematous cholecystitis is caused by gas-forming micro-organisms, primarily in patients with immunosuppression and diabetes mellitus. It leads to a signature radiological finding with air in gall bladder wall as described in this report. Clinicians should be aware of this critical differential diagnosis.